Every day, Global University Venturing rounds up investments from across the university innovation ecosystem in its deal net.

TargED Biopharmaceuticals, a Netherlands-based thermobolytic clot treatment spinout of UMC Utrecht, picked up €39m ($44.2m) in a series A round today backed by the UMC-backed Utrecht Health Seed Fund. The round was co-led by Andrea Partners, Fund+, Hadean Ventures, Inkef Capital and Sunstone Life Science Ventures. It also included BioGeneration Ventures-managed First Fund and Curie…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).